Complete Filing Data
LENZ Therapeutics, Inc. reported Stockholders Equity of $284.34 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean LENZ Therapeutics, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Income * | -$82.1M | -$49.8M | -$70.0M | -$101.1M | -$70.8M | -$68.4M |
| Revenue * | $19.1M | $0.00 | ||||
| Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | $46.0K | $190.0K | $6.0K | -$1.0M | $0.00 | |
| Research And Development Expense | $18.7M | $29.8M | $59.5M | $72.8M | $37.9M | $9.1M |
| Operating Income Loss | -$91.1M | -$58.6M | -$72.4M | -$105.6M | -$60.4M | -$13.5M |
| Nonoperating Income Expense | $9.5M | $8.8M | $2.3M | $4.6M | -$10.3M | -$54.9M |
| Operating Expenses | $58.6M | $72.4M | $105.6M | $60.4M | $13.5M | |
| Other Nonoperating Income Expense | -$243.0K | $289.0K | $93.0K | $4.6M | $24.0K | |
| Net Income Loss And Comprehensive Income Loss | -$123.6M | -$102.1M | -$70.8M | -$68.4M | ||
| General And Administrative Expense | $41.0M | $32.9M | $22.5M | $4.4M | ||
| Selling General And Administrative Expense | $91.1M | $28.8M | $12.9M | |||
| Comprehensive Income Net Of Tax | -$82.1M | -$49.6M | -$70.0M | |||
| Restructuring Costs | $62.1M | $0.00 | ||||
| Cost Of Goods And Services Sold | $418.0K | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$16.7M | -$14.9M | -$14.6M | -$10.2M | -$10.3M | -$16.6M | -$18.9M | -$14.7M | -$12.7M | -$24.7M | -$25.9M | -$25.8M | -$14.6M | -$17.5M | -$19.7M | |||
| Revenue * | $12.5M | $5.0M | $0.00 | $0.00 | ||||||||||||||
| Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | $189.0K | -$85.0K | -$73.0K | $585.0K | -$61.0K | -$7.0K | $9.0K | -$14.0K | $0.00 | -$563.0K | -$724.0K | -$309.0K | $0.00 | $0.00 | ||||
| Research And Development Expense | $3.8M | $9.1M | $5.8M | $6.5M | $6.9M | $10.5M | $17.0M | $12.6M | $10.3M | $18.3M | $17.8M | $18.2M | $8.7M | $12.7M | $5.4M | $2.3M | $423.0K | |
| Operating Income Loss | -$18.9M | -$16.9M | -$16.9M | -$12.9M | -$14.4M | -$16.1M | -$19.9M | -$15.0M | -$12.6M | -$26.2M | -$26.8M | -$26.0M | -$14.6M | -$17.5M | -$9.4M | -$3.8M | -$1.3M | |
| Nonoperating Income Expense | $2.2M | $2.4M | $2.3M | $2.7M | $4.1M | -$560.0K | $985.0K | $233.0K | -$54.0K | $1.5M | $840.0K | $123.0K | $10.0K | $4.0K | -$10.3M | $380.0K | -$20.0K | |
| Operating Expenses | $31.4M | $21.9M | $16.9M | $12.9M | $14.4M | $16.1M | $19.9M | $15.0M | $12.6M | $26.2M | $26.8M | $26.0M | $14.6M | $17.5M | $9.4M | $3.8M | $1.3M | |
| Other Nonoperating Income Expense | -$14.0K | $199.0K | -$11.0K | -$6.0K | $1.6M | -$1.3M | -$101.0K | -$18.0K | -$54.0K | $1.5M | $840.0K | $123.0K | $10.0K | $4.0K | ||||
| Net Income Loss And Comprehensive Income Loss | -$22.3M | -$55.1M | -$23.4M | -$25.2M | -$26.7M | -$26.1M | -$14.6M | -$17.5M | -$19.7M | -$3.4M | -$1.3M | -$141.0K | ||||||
| General And Administrative Expense | $11.3M | $7.5M | $7.6M | $7.9M | $9.0M | $7.7M | $5.9M | $4.9M | $4.0M | $1.5M | $869.0K | |||||||
| Selling General And Administrative Expense | $27.6M | $12.8M | $11.1M | $6.5M | $7.4M | $5.6M | $2.9M | $2.3M | $2.3M | |||||||||
| Comprehensive Income Net Of Tax | -$16.5M | -$15.0M | -$14.7M | -$9.6M | -$10.3M | -$16.7M | -$18.9M | -$14.7M | -$12.7M | |||||||||
| Restructuring Costs | $11.3M | $37.2M | $2.6M | $0.00 | $0.00 | $0.00 | ||||||||||||
| Cost Of Goods And Services Sold |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Stockholders Equity | $284.3M | $204.1M | -$92.7M | -$24.2M | $384.1M | -$65.4M | -$2.2M |
| Cash And Cash Equivalents At Carrying Value | $25.2M | $20.2M | $35.1M | $47.7M | $377.0M | $19.8M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $4.9M | -$14.9M | -$9.3M | -$329.2M | $358.9M | $19.8M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $186.0M | $49.4M | $378.7M | $19.8M | $6.0K | ||
| Restricted Cash Current | $0.00 | $114.0K | $0.00 | $1.7M | $1.7M | $35.0K | |
| Retained Earnings Accumulated Deficit | -$227.1M | -$145.0M | -$95.2M | -$242.4M | -$141.4M | -$70.6M | |
| Property Plant And Equipment Net | $1.2M | $651.0K | $54.0K | $22.6M | $6.5M | $1.5M | |
| Prepaid Expense And Other Assets Current | $5.8M | $2.8M | $1.5M | $7.1M | $4.8M | $1.3M | |
| Liabilities Current | $21.2M | $10.4M | $18.5M | $13.0M | $12.1M | $32.0M | |
| Liabilities And Stockholders Equity | $305.9M | $215.3M | $70.4M | $321.9M | $402.0M | $22.6M | |
| Liabilities | $21.5M | $11.2M | $19.7M | $25.6M | $17.9M | $32.4M | |
| Assets Current | $301.4M | $211.9M | $67.2M | $275.4M | $381.7M | $21.1M | |
| Assets | $305.9M | $215.3M | $70.4M | $321.9M | $402.0M | $22.6M | |
| Accounts Payable Current | $4.2M | $4.3M | $5.7M | $2.6M | $2.5M | $630.0K | |
| Accretion Amortization Of Discounts And Premiums Investments | $3.4M | $4.0M | $1.1M | $1.6M | $0.00 | ||
| Common Stock Value | $1.0K | $1.0K | $10.0K | $1.0K | $1.0K | ||
| Operating Lease Right Of Use Asset | $734.0K | $1.3M | $318.0K | $5.6M | $11.6M | ||
| Operating Lease Liability Noncurrent | $350.0K | $814.0K | $192.0K | $1.7M | $5.8M | ||
| Accumulated Other Comprehensive Income Loss Net Of Tax | $242.0K | $196.0K | $6.0K | -$1.0M | $0.00 | ||
| Other Assets Noncurrent | $2.5M | $1.4M | $21.0K | $1.3M | $454.0K | ||
| Unrealized Gain Loss On Investments | $1.0M | -$1.0M | |||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $25.2M | $20.3M | $35.1M | $44.4M | |||
| Available For Sale Securities Debt Securities Current | $220.5M | $0.00 | |||||
| Employee Related Liabilities Current | $1.5M | $3.8M | $2.7M | $466.0K | |||
| Purchases Of Property And Equipment Included In Accounts Payable | $0.00 | -$36.0K | -$75.0K | -$35.0K | |||
| Operating Lease Liability Current | $285.0K | $4.0M | $5.5M | ||||
| Accrued Expenses And Other Current Liabilities | $2.7M | $1.9M | $886.0K | $126.0K | |||
| Non Cash Lease Expense | $4.3M | $6.0M | $1.5M | ||||
| Accrued Research Costs | $0.00 | $720.0K | $633.0K | $1.8M | |||
| Restricted Cash Noncurrent | $114.0K | $1.7M | $1.7M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $193.9M | $206.4M | $192.0M | $215.3M | $192.9M | $198.2M | -$69.6M | -$51.2M | -$36.7M | $316.5M | $338.5M | $361.3M | $400.1M | $379.2M | -$84.1M | -$4.8M | -$1.4M | -$2.4M | |
| Cash And Cash Equivalents At Carrying Value | $25.4M | $37.6M | $23.0M | $41.0M | $84.0M | $200.4M | $183.0M | $128.5M | $69.8M | $56.4M | $75.2M | $185.1M | $394.8M | $382.0M | $177.0M | $10.5M | $13.6M | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $2.9M | $165.3M | $70.4M | -$191.9M | $157.3M | ||||||||||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $184.7M | $130.2M | $71.5M | $58.1M | $76.9M | $186.8M | $395.0M | $382.1M | $177.2M | $10.6M | $13.7M | ||||||||
| Restricted Cash Current | $0.00 | $114.0K | $114.0K | $114.0K | $114.0K | $114.0K | $1.7M | $1.7M | $1.7M | $1.7M | $1.7M | $1.7M | $149.0K | $149.0K | $149.0K | $35.0K | $35.0K | ||
| Retained Earnings Accumulated Deficit | -$191.2M | -$174.5M | -$159.6M | -$132.4M | -$122.1M | -$111.9M | -$344.1M | -$321.7M | -$266.3M | -$217.8M | -$193.1M | -$167.2M | -$122.4M | -$107.8M | |||||
| Property Plant And Equipment Net | $1.3M | $1.2M | $926.0K | $372.0K | $164.0K | $49.0K | $12.5M | $18.0M | $33.1M | $13.3M | $10.5M | $9.4M | $5.8M | $2.3M | |||||
| Prepaid Expense And Other Assets Current | $3.9M | $4.0M | $3.8M | $3.5M | $3.1M | $3.3M | $4.8M | $2.9M | $6.2M | $6.8M | $4.4M | $4.6M | $6.3M | $2.6M | |||||
| Liabilities Current | $16.3M | $10.4M | $8.6M | $7.7M | $8.6M | $18.9M | $12.5M | $12.3M | $14.3M | $13.5M | $12.1M | $12.8M | $11.3M | $7.9M | |||||
| Liabilities And Stockholders Equity | $210.7M | $217.3M | $201.3M | $224.0M | $202.6M | $217.3M | $266.2M | $287.0M | $310.0M | $334.8M | $353.8M | $378.6M | $416.2M | $387.1M | |||||
| Liabilities | $16.8M | $11.0M | $9.2M | $8.7M | $9.7M | $19.2M | $62.2M | $62.9M | $33.8M | $18.4M | $15.3M | $17.3M | $16.0M | $7.9M | |||||
| Assets Current | $207.0M | $213.6M | $197.9M | $220.7M | $199.4M | $216.7M | $238.8M | $251.2M | $270.3M | $298.5M | $326.6M | $343.8M | $401.2M | $384.8M | |||||
| Assets | $210.7M | $217.3M | $201.3M | $224.0M | $202.6M | $217.3M | $266.2M | $287.0M | $310.0M | $334.8M | $353.8M | $378.6M | $416.2M | $387.1M | |||||
| Accounts Payable Current | $4.3M | $2.9M | $3.7M | $2.8M | $4.4M | $7.1M | $3.8M | $2.7M | $2.0M | $4.0M | $3.6M | $3.1M | $1.8M | $4.0M | |||||
| Accretion Amortization Of Discounts And Premiums Investments | $1.1M | $275.0K | $0.00 | -$45.0K | |||||||||||||||
| Common Stock Value | $1.0K | $1.0K | $1.0K | $0.00 | $0.00 | $0.00 | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | |||||
| Operating Lease Right Of Use Asset | $847.0K | $959.0K | $1.1M | $1.5M | $1.7M | $578.0K | $13.2M | $15.8M | $4.0M | $7.1M | $8.6M | $10.1M | $9.1M | ||||||
| Operating Lease Liability Noncurrent | $461.0K | $569.0K | $673.0K | $953.0K | $1.1M | $156.0K | $49.7M | $50.6M | $1.4M | $2.5M | $3.3M | $4.5M | $4.7M | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | $227.0K | $38.0K | $123.0K | $523.0K | -$62.0K | -$1.0K | -$95.0K | -$271.0K | -$469.0K | -$1.6M | -$1.0M | -$309.0K | |||||||
| Other Assets Noncurrent | $1.6M | $1.6M | $1.4M | $1.4M | $1.4M | $0.00 | $355.0K | $889.0K | $844.0K | $335.0K | $711.0K | $12.0K | $11.0K | ||||||
| Unrealized Gain Loss On Investments | $176.0K | $198.0K | $579.0K | -$563.0K | -$724.0K | -$309.0K | |||||||||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $25.4M | $37.7M | $23.2M | $41.2M | $84.1M | $200.5M | $42.8M | $74.4M | $114.8M | ||||||||||
| Available For Sale Securities Debt Securities Current | $176.1M | $112.1M | $12.9M | $30.7M | $51.0M | $118.2M | $194.3M | $235.3M | $247.1M | $154.1M | |||||||||
| Employee Related Liabilities Current | $1.9M | $2.3M | $1.3M | $3.3M | $2.2M | $1.0M | $1.7M | $723.0K | |||||||||||
| Purchases Of Property And Equipment Included In Accounts Payable | -$4.7M | -$109.0K | -$187.0K | ||||||||||||||||
| Operating Lease Liability Current | $3.4M | $2.9M | $3.1M | $4.6M | $4.9M | $5.6M | $4.8M | ||||||||||||
| Accrued Expenses And Other Current Liabilities | $3.4M | $3.8M | $7.3M | $1.3M | $882.0K | $1.2M | $1.3M | $3.1M | |||||||||||
| Non Cash Lease Expense | $1.6M | $1.5M | |||||||||||||||||
| Accrued Research Costs | $30.0K | $577.0K | $596.0K | $353.0K | $460.0K | $1.9M | $1.7M | ||||||||||||
| Restricted Cash Noncurrent | $1.7M | $1.7M | $1.7M | $1.7M | $1.7M | $1.7M |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Share Based Compensation | $12.5M | $6.4M | $1.3M | $13.5M | $7.9M | $177.0K |
| Payments To Acquire Property Plant And Equipment | $827.0K | $468.0K | $30.0K | $6.6M | $5.7M | $1.5M |
| Net Cash Provided By Used In Operating Activities | -$69.2M | -$59.4M | -$60.4M | -$88.0M | -$52.9M | -$8.7M |
| Net Cash Provided By Used In Investing Activities | -$75.7M | -$154.5M | -$29.6M | -$241.9M | -$5.7M | -$1.5M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $3.0M | -$25.0K | -$761.0K | $3.2M | $3.9M | $1.3M |
| Increase Decrease In Accounts Payable | -$90.0K | -$4.3M | $856.0K | $194.0K | $1.8M | $594.0K |
| Net Cash Provided By Used In Financing Activities | $149.7M | $199.0M | $80.7M | $597.0K | $417.5M | $30.1M |
| Proceeds From Stock Options Exercised | $1.1M | $4.0M | $203.0K | $20.0K | $28.0K | |
| Increase Decrease In Employee Related Liabilities | -$2.3M | $1.1M | $2.2M | $466.0K | ||
| Increase Decrease In Accrued Expenses And Other Current Liabilities And Other Liabilities | $1.8M | $94.0K | $257.0K | $171.0K | ||
| Increase Decrease In Accrued Research Costs | -$720.0K | $87.0K | -$1.1M | $1.8M | ||
| Proceeds From Stock Plans | $873.0K | $0.00 | $157.0K | $656.0K | $306.0K | |
| Increase Decrease In Operating Lease Liability | -$41.4M | -$5.5M | -$1.8M | |||
| Payments To Acquire Marketable Securities | $28.1M | $405.5M | $0.00 | |||
| Proceeds From Sale And Maturity Of Marketable Securities | $263.4M | $170.3M | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|
| Share Based Compensation | $2.6M | $947.0K | $142.0K | $3.3M | $1.0M |
| Payments To Acquire Property Plant And Equipment | $110.0K | $0.00 | $6.0K | $3.3M | $360.0K |
| Net Cash Provided By Used In Operating Activities | -$16.0M | -$23.9M | -$12.8M | -$21.2M | -$8.1M |
| Net Cash Provided By Used In Investing Activities | $18.9M | $18.0M | -$6.0K | -$170.7M | -$360.0K |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $996.0K | $518.0K | -$426.0K | $71.0K | $1.8M |
| Increase Decrease In Accounts Payable | -$771.0K | -$1.3M | -$567.0K | $582.0K | $83.0K |
| Net Cash Provided By Used In Financing Activities | $44.0K | $171.3M | $83.2M | $0.00 | $165.8M |
| Proceeds From Stock Options Exercised | $44.0K | $430.0K | $203.0K | $268.0K | |
| Increase Decrease In Employee Related Liabilities | -$2.5M | -$1.7M | -$179.0K | ||
| Increase Decrease In Accrued Expenses And Other Current Liabilities And Other Liabilities | $1.9M | $323.0K | $881.0K | ||
| Increase Decrease In Accrued Research Costs | -$124.0K | $1.2M | $1.2M | ||
| Proceeds From Stock Plans | |||||
| Increase Decrease In Operating Lease Liability | -$1.3M | -$1.1M | |||
| Payments To Acquire Marketable Securities | $28.1M | $167.4M | |||
| Proceeds From Sale And Maturity Of Marketable Securities | $71.7M | $0.00 |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Diluted EPS * | -$2.85 | -$2.34 | -$35.71 | -$1.84 | -$2.45 | -$29.93 |
| Weighted Average Number Of Shares Outstanding Basic | 28.8M | 21.3M | 2.0M | 54.9M | 28.9M | |
| Weighted Average Number Of Diluted Shares Outstanding | 28.8M | 21.3M | 2.0M | 54.9M | 28.9M | |
| Earnings Per Share Basic | $-2.85 | $-2.34 | $-35.71 | $-1.84 | $-2.45 | |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Common Stock Shares Outstanding | 31.3M | 27.5M | 2.0M | 58.2M | 58.0M | 10.3M |
| Common Stock Shares Issued | 31.3M | 27.5M | 2.0M | 58.2M | 58.2M | 10.3M |
| Common Stock Shares Authorized | 300.0M | 300.0M | 16.0M | 300.0M | 300.0M | 80.0M |
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 0.00 |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | -$0.59 | -$0.53 | -$0.53 | -$0.38 | -$0.40 | -$3.53 | -$9.62 | -$7.53 | -$6.50 | -$0.45 | -$0.48 | -$0.48 | -$0.28 | -$3.45 | -$5.75 | -$1.00 | -$0.56 |
| Weighted Average Number Of Shares Outstanding Basic | 28.5M | 28.1M | 27.5M | 27.2M | 25.6M | 4.7M | 2.0M | 2.0M | 2.0M | 55.2M | 54.6M | 54.0M | 52.8M | 5.1M | |||
| Weighted Average Number Of Diluted Shares Outstanding | 28.5M | 28.1M | 27.5M | 27.2M | 25.6M | 4.7M | 2.0M | 2.0M | 2.0M | 55.2M | 54.6M | 54.0M | 52.8M | 5.1M | |||
| Earnings Per Share Basic | $-0.59 | $-0.53 | $-0.53 | $-0.38 | $-0.40 | $-3.53 | $-9.62 | $-7.53 | $-6.50 | $-0.45 | $-0.48 | $-0.48 | $-0.28 | $-3.45 | |||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||
| Common Stock Shares Outstanding | 28.6M | 28.5M | 27.5M | 27.5M | 25.8M | 25.5M | 58.0M | 58.0M | 58.2M | 58.1M | 58.2M | 58.0M | 58.1M | 56.0M | |||
| Common Stock Shares Issued | 28.6M | 28.5M | 27.5M | 27.5M | 25.9M | 25.5M | 58.0M | 58.0M | 58.2M | 58.1M | 58.2M | 58.0M | 58.1M | 56.0M | |||
| Common Stock Shares Authorized | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | |||
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | |||||||||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $12.5M | $6.4M | $1.3M | $13.5M | $7.9M | $177.0K |
| Vesting Of Early Exercised Stock Options | $63.0K | $131.0K | $144.0K | $9.0K | ||
| Stock Issued During Period Value Stock Options Exercised | $1.1M | $100.0K | $20.0K | $42.0K | ||
| Additional Paid In Capital | $511.2M | $348.9M | $2.5M | $539.7M | $525.4M | $5.2M |
| Noncash Or Part Noncash Vesting Of Early Exercised Stock Options | $63.0K | $131.0K | $144.0K | $9.0K | ||
| Depreciation And Amortization | $2.4M | $2.4M | $734.0K | $121.0K | ||
| Investment Income Interest | $9.8M | $8.6M | $2.2M | |||
| Stock Issued During Period Value Stock Options Exercised Early | $44.0K | $76.0K | $76.0K | |||
| Stock Issued During Period Value Employee Stock Purchase Plan | $873.0K | $157.0K | $656.0K | $306.0K | ||
| Repurchase Of Unvested Early Exercised Shares | 67.0K | 79.0K | 0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $3.5M | $2.8M | $2.6M | $2.2M | $1.6M | $947.0K | $494.0K | $189.0K | $142.0K | $3.2M | $3.4M | $3.3M | $2.4M | $2.0M | $1.0M | $36.0K | $1.0K |
| Vesting Of Early Exercised Stock Options | $5.0K | $18.0K | $25.0K | $27.0K | $30.0K | $51.0K | $20.0K | $42.0K | $7.0K | $5.0K | |||||||
| Stock Issued During Period Value Stock Options Exercised | $598.0K | $196.0K | $44.0K | $57.0K | $3.4M | $10.0K | $16.0K | $18.0K | $19.0K | $5.0K | $13.0K | $21.0K | |||||
| Additional Paid In Capital | $384.9M | $380.9M | $351.5M | $347.1M | $315.1M | $310.1M | $548.2M | $546.1M | $543.0M | $535.9M | $532.6M | $528.8M | $522.6M | $487.0M | |||
| Noncash Or Part Noncash Vesting Of Early Exercised Stock Options | $25.0K | $51.0K | $7.0K | ||||||||||||||
| Depreciation And Amortization | $654.0K | $440.0K | $90.0K | ||||||||||||||
| Investment Income Interest | $2.2M | $2.2M | $2.3M | $2.7M | $2.5M | $788.0K | $1.1M | $251.0K | $0.00 | ||||||||
| Stock Issued During Period Value Stock Options Exercised Early | $6.0K | $19.0K | $19.0K | $19.0K | $28.0K | $10.0K | $19.0K | $19.0K | $19.0K | ||||||||
| Stock Issued During Period Value Employee Stock Purchase Plan | $225.0K | $157.0K | $414.0K | ||||||||||||||
| Repurchase Of Unvested Early Exercised Shares | 8.0K | 0.00 |
Most recent annual filing with the SEC: March 24, 2026
Data sourced from SEC EDGAR public filings as of August 5, 2026.